Astellas' Once-Daily Prograf Receives Mixed Decisions For Three Prophylaxis Claims
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma's once-daily immunosuppressant Prograf MR, a modified-release formulation of tacrolimus, is "approvable" in the U.S. for prophylaxis of organ rejection in kidney and liver transplantation but "not approvable" for heart transplant patients, the company said Jan. 23